Nykode Therapeutics receives new US patent for VB10.NEO individualized cancer vaccine program

• Nykode Therapeutics received a new U.S. patent that strengthens intellectual property protection for its fully individualized VB10.NEO cancer vaccine program.
• The patent expands the company’s protection in the U.S. for the VB10.NEO approach.
• The move supports Nykode’s strategy to defend its personalized cancer vaccine platform in a key market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nykode Therapeutics AS published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.